Sarcoma – VJRegenMed

PiggyBac Transposon-generated CAR T-cells in solid tumors

Simon Ng — Thu, 21 Apr 2022 16:45:47 +0000

Shigeki Yagyu, MD, PhD, Kyoto Prefectural University of Medicine, Kyoto, Japan, discusses the future of PiggyBac transposon-mediated chimeric antigen receptor (CAR) T-cell therapies. A clinical trial is imminently underway to assess a CAR T-cell therapy based on PiggyBac transposon technology in HER2+ bone sarcoma and gynecological cancers. Preclinical studies assessing the treatment has yielded promising results in sarcoma and brain tumors in terms of efficacy and long-term functionality. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs

admin_vjr_user — Sat, 03 Jul 2021 11:01:11 +0000

Jo Brewer, PhD, Adaptimmune, Philadelphia, PA, provides an overview of the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, which involves genetically engineering T-cell receptors to enhance their ability to recognize specific peptide antigens, thus increasing the immune system’s ability to recognize and target cancer cells. This technology is currently being investigated in clinical trials for the treatment of a range of solid tumors, such as the Phase II SPEARHEAD-1 trial (NCT04044768) in patients with synovial sarcoma. A novel human leukocyte antigen (HLA)-independent T-cell receptor (TCR) platform is also currently in development, which would allow the targeting of tumor cells without the need for HLA subtyping. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS

admin_vjr_user — Sat, 03 Jul 2021 11:01:10 +0000

Jo Brewer, PhD, Adaptimmune, Philadelphia, PA, introduces the ongoing Phase II SPEARHEAD-1 trial (NCT04044768), assessing the efficacy and safety of ADP-A2M4 in patients with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS). The ADP-A2M4 SPEAR T-cell therapy targets the MAGE- A4 antigen presented by HLA-A2+ patients. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

Adaptimmune: SPEAR T-cells

admin_vjr_user — Tue, 03 Nov 2020 17:39:49 +0000

TCR T-cell therapies (SPEAR T-cells) hold the potential to treat a wide range of cancers. In this video, Helen Tayton-Martin, Chief Business Officer, Adaptimmune, Oxford, UK. discusses the SPEAR T-cells currently under development with Adaptimmune. Dr Taytor-Martin goes on to discuss Adaptimmune’s partnership with GlaxoSmithKline (GSK) and recent advances such as the SURPASS trial (NCT04044859) which investigated ADP-A2M4CD8 in HLA-A2+ subjects with MAGE-A4 positive tumors. This interview took place during the 2020 Meeting on the Mesa congress.